Emergency response! Sunflower actual controller "homicide"

On April 10, according to media reports, Guan Yanbin, the former chairman of the listed company and Heilongjiang sunflower Pharmaceutical Group Co., Ltd (hereinafter referred to as "sunflower pharmaceutical"), was arrested by the people's Procuratorate of Ranghulu District of Daqing city on suspicion of intentional homicide The time for the public security organ to request the arrest was January 29 The case is still under investigation At the same time of arousing social concern, we received the letter of concern about sunflower Pharmaceutical Group Co., Ltd issued by the management department of small and medium-sized board company of Shenzhen Stock Exchange (No 214 [2019] of small and medium-sized board concern letter) In response to the relevant matters involved in the letter of concern, sunflower pharmaceutical industry made a written reply and issued an enterprise announcement The specific contents are as follows: reply to the letter of concern of Shenzhen Stock Exchange 1 Whether the influence of the above-mentioned matters on the stability of the company's control power may lead to the change of the actual controller of the company, and the countermeasures your company has taken and plans to take Reply: the actual controller of the company is Mr Guan Yanbin Up to now, Mr Guan Yanbin directly holds 66482952 shares of the company, with a shareholding ratio of 11.38%; meanwhile, Mr Guan Yanbin holds 265200000 shares of the company, with a shareholding ratio of 45.41%, and Heilongjiang Jinkui Investment Co., Ltd (with a shareholding ratio of 2, 4 million shares, with a shareholding ratio of 4.11%) indirectly holding the company's shares The specific shareholding information is as follows: Mr Guan Yanbin's above shares have not changed, the company's control power is stable, and the actual controller has not changed The company will urge Mr Guan Yanbin to inform the company of any change of control in a timely manner, and the company will disclose compliance in accordance with relevant regulatory regulations 2 Whether the relevant parties are restricted in exercising shareholder's rights, including but not limited to voting rights Reply: Mr Guan Yanbin's exercise of shareholder's rights is not restricted At the same time, Mr Guan Yanbin met with his lawyer in accordance with the law, signed relevant documents and effectively exercised his shareholders' rights in accordance with the law 3 Whether the company's production and operation activities are affected Reply: the company issued a notice on January 1, 2019 that the board of directors of sunflower Pharmaceutical Group Co., Ltd (hereinafter referred to as "the company") received a written resignation report from Mr Guan Yanbin, chairman and general manager of the company on December 28, 2018 Mr Guan Yanbin applied to resign as a director, chairman and general manager of the third board of directors of the company, and at the same time resigned as a member of the strategy committee of the third board of directors After his resignation, Mr Guan Yanbin has ceased to hold a post in the listed company and remains the actual controller of the company The company has elected and appointed the chairman and general manager of the company in accordance with relevant laws, regulations and the articles of association The company's production and operation are normal 4 Whether the company fails to disclose or does not disclose in a timely manner, and whether it violates the relevant provisions of the stock listing rules of the exchange and the guidelines for the standardized operation of listed companies on the SME board Reply of the company: the company issued the 2018 annual report on March 21, 2019, and disclosed in the "XIII Punishment and rectification situation" in "section V important matters": the actual controller of the company caused physical injury due to personal reasons and disputes with others, and was taken compulsory measures by the judicial authorities He does not hold the office of director, supervisor or senior officer in the listed company, and the incident has not affected the normal production and operation activities of the listed company The exercise of shareholders' rights shall not be affected According to the company's self-examination, the company does not have the situation that the disclosure is not disclosed or not timely, and the information disclosure conforms to the relevant provisions of the Shenzhen Stock Exchange's stock listing rules and the guidelines for the standardized operation of listed companies on the SME board 5 Other matters that the company thinks should be explained Company reply: the company has paid attention to the relevant media reports According to the relevant family members, at present, the case is still under investigation and processing, and both parties have no major problems This case was caused by personal disputes, and did not involve a third party unrelated to the family members, and did not involve the business operation of the company The company's operation and management are orderly and effective, with stable control power; the first quarter's operating performance keeps growing, and keeps improving In response to internal employees, sunflower pharmaceutical released the first quarter of 2019 sunflower performance forecast, with the net profit attributable to shareholders of listed companies ranging from 153.824 million yuan to 168.4739 million yuan, an increase of + 5% to + 15% compared with 146.499 million yuan in the same period of last year And in the plan of public opinion fermentation, sunflower pharmaceutical industry, in line with the attitude of being responsible for the internal staff, wrote a letter to all sunflower employees The following is the internal circulation information: statement: This article is the integration content, the point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.